Influence
April 1, 2025

Medicare Beneficiary Receipt of Methadone by Drive Time to Opioid Treatment Programs

Kosali Simon, PhD

Published in JAMA Network Open. Here is a link to the article.

Regenstrief Institute authors: Kosali Simon, PhD, M.A.

This study examined how proximity to opioid treatment programs (OTPs) impacts methadone receipt among Medicare beneficiaries diagnosed with opioid use disorder (OUD) in 2020. Using Medicare claims and drive-time data, researchers found that methadone receipt decreased as distance to an OTP increased. Urban beneficiaries living within 5 minutes of an OTP were 54% more likely to receive methadone than those 15 minutes away; in rural areas, the drop was 27%. A threshold effect was observed at a 20-minute drive time, beyond which the likelihood of methadone receipt leveled off and showed minimal differences between urban and rural populations. The findings highlight the importance of OTP location in improving access to OUD treatment.

Authors

Jonathan Cantor 1Helin G Hernandez 1Aaron Kofner 2Julie Lai 1Denis Agniel 1Kosali I Simon 3Bradley D Stein 4Erin A Taylor 1

Affiliations

1RAND, Santa Monica, California.

2RAND, Arlington, Virginia.

3O’Neill School of Public and Environmental Affairs, Indiana University, Bloomington.

4RAND, Pittsburgh, Pennsylvania.

Related News

Ontology 2.0 deepens LOINC®-SNOMED collaboration, speeds global lab interoperability

Ontology 2.0 deepens LOINC®-SNOMED collaboration, speeds global lab interoperability

INDIANAPOLIS, US and LONDON, UK – Regenstrief Institute and SNOMED International have released LOINC® Ontology 2.0, the next version

Kurt Kroenke, M.D., and Paul Musey, M.D., M.S.

Treating anxiety could curb unnecessary ED visits for low-risk chest pain

Chest pain ranks as the second most common reason for emergency department (ED) visits, making it a key concern

Dr. Rachel Patzer, Dr. Virginia Caine, Claire Fiddian-Green and Phaedra Schaffer-Corso

Regenstrief leaders join 2025 Leadership Exchange delegation in Washington, D.C.

Regenstrief Institute President and Chief Executive Officer Rachel Patzer, PhD, MPH, was part of a contingent of more than